Literature DB >> 24236616

Using Mendelian randomization to assess and develop clinical interventions: limitations and benefits.

Stephen Burgess1, Anders Malarstig.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 24236616     DOI: 10.2217/cer.13.14

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


× No keyword cloud information.
  3 in total

1.  What do hypnotics cost hospitals and healthcare?

Authors:  Daniel F Kripke
Journal:  F1000Res       Date:  2017-04-21

2.  Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease.

Authors:  Lasse Folkersen; Eric Fauman; Maria Sabater-Lleal; Rona J Strawbridge; Mattias Frånberg; Bengt Sennblad; Damiano Baldassarre; Fabrizio Veglia; Steve E Humphries; Rainer Rauramaa; Ulf de Faire; Andries J Smit; Philippe Giral; Sudhir Kurl; Elmo Mannarino; Stefan Enroth; Åsa Johansson; Sofia Bosdotter Enroth; Stefan Gustafsson; Lars Lind; Cecilia Lindgren; Andrew P Morris; Vilmantas Giedraitis; Angela Silveira; Anders Franco-Cereceda; Elena Tremoli; Ulf Gyllensten; Erik Ingelsson; Søren Brunak; Per Eriksson; Daniel Ziemek; Anders Hamsten; Anders Mälarstig
Journal:  PLoS Genet       Date:  2017-04-03       Impact factor: 5.917

3.  The Effect of Circulating Zinc, Selenium, Copper and Vitamin K1 on COVID-19 Outcomes: A Mendelian Randomization Study.

Authors:  Maria K Sobczyk; Tom R Gaunt
Journal:  Nutrients       Date:  2022-01-06       Impact factor: 6.706

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.